Form 4: Veracyte CEO Sells Shares Under Pre-Arranged 10b5-1 Plan

Veracyte CEO Marc Stapley sold 7,667 shares of common stock for approximately $30.41 per share under a pre-arranged Rule 10b5-1 trading plan.

Summary

• Marc Stapley, the Chief Executive Officer and a Director of Veracyte, Inc. (VCYT), reported a sale of common stock.
• The transaction involved the disposition of 7,667 shares of Veracyte common stock.
• The shares were sold at a weighted average price of $30.4073 per share, with individual sale prices ranging from $30.22 to $30.66.
• Following this transaction, Marc Stapley beneficially owns 334,185 shares of Veracyte common stock.
• The sale was executed on September 4, 2025, pursuant to a Rule 10b5-1 plan adopted by Mr. Stapley on September 13, 2024.

Sentiment

Score: 5

Explanation: The sentiment is neutral. While it's an insider sale, it was conducted under a pre-arranged 10b5-1 plan, which typically indicates a planned liquidity event rather than a reaction to new negative information. This mitigates the negative signal often associated with insider selling.

Positives

• The transaction was conducted under a Rule 10b5-1 plan, indicating that the sale was pre-scheduled and not based on material non-public information, which enhances transparency and reduces the perception of opportunistic insider trading.

Negatives

• Insider selling, even when pre-planned, can sometimes be interpreted by investors as a lack of confidence in the company's near-term prospects, potentially creating negative sentiment.

Risks

• The sale of shares by a key executive could lead to negative market perception or increased scrutiny from investors, potentially impacting the stock price.

Stakeholder Impact

• Shareholders may interpret the insider sale differently; some may view it as a routine liquidity event due to the 10b5-1 plan, while others might perceive it as a slight negative signal regarding future company performance.

Key Dates

Recommendation

A 'hold' recommendation is appropriate because the insider sale was executed under a pre-arranged 10b5-1 plan, which suggests a planned personal financial management strategy rather than a reaction to new, material information. While insider sales can sometimes be a negative signal, the pre-planned nature typically reduces its immediate impact on investment decisions. Investors should monitor future company performance and other filings for more substantive signals.

Keywords

Veracyte, VCYT, Marc Stapley, Insider Sale, Form 4, 10b5-1 Plan, CEO, Director, Stock Transaction